TY - JOUR
T1 - mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene
T2 - from the laboratory into the clinic.
AU - Fisher, Paul B.
AU - Gopalkrishnan, Rahul V.
AU - Chada, Sunil
AU - Ramesh, Rajagopal
AU - Grimm, Elizabeth A.
AU - Rosenfeld, Myrna R.
AU - Curiel, David T.
AU - Dent, Paul
N1 - Funding Information:
Acknowledgments We thank our numerous colleagues for their valuable contributions to the research that has provided the foundation for our current understanding of mda-7/IL-24. Dr. Fisher’s research is supported by National Institutes of Health, National Cancer Institute grants CA35675, CA97318 and CA98712, DOD Prostate Cancer Research Program grant DAMD 024-0041, the Samuel Waxman Cancer Research Foundation, the Lustgarten Foundation for Pancreatic Cancer Research, the Michael and Stella Chernow Endowment and a Sponsored Research Agreement with Introgen Therapeutics, Inc. Dr. Fisher is the Michael and Stella Chernow Urological Cancer Research Scientist. Dr. Chada’s research is supported by National Cancer Institute grants CA89778, CA86587 and CA97598, and Introgen Therapeutics, Inc. Dr. Ramesh’s research is supported by Texas Higher Education Coordinating Board ATP/ARP grant 003657-0078-2001, a Career Development Award from The University of Texas M.D. Anderson Cancer Center SPORE in Lung Cancer P50-CA70907-5, a University of Texas M.D. Anderson Cancer Center Institutional Research Grant, a grant from the W. M. Keck Foundation Fund for Human Cancer Gene Prevention and Therapy and a sponsored research agreement with Introgen Therapeutics, Inc. Dr. Grimm is supported by National Cancer Institute grants CA89778 and CA90282. Dr. Curiel’s research is supported by National Institutes of Health grants HL67962, CA89019, CA86881, AG021875 and CA090547. Dr. Dent’s research is supported by National Institutes of Health grants DK52825, CA88906 and CA72955. Dr. Dent holds the Universal Leaf Professorship in Signaling. References
PY - 2003
Y1 - 2003
N2 - An obstacle to effective gene-based cancer therapies is the limited number of cancer-specific growth suppressing and apoptosis-inducing genes. Using a differentiation induction subtraction hybridization (DISH) approach with human melanoma cells, melanoma differentiation associated (mda) genes were isolated that display elevated expression as a function of irreversible growth arrest, cancer reversion and terminal differentiation. This screening paradigm resulted in the cloning of mda-7 in the context of terminal differentiation of human melanoma cells. Based on its structure, chromosomal location, sequence homology and cytokine-like properties, mda-7 has now been renamed IL-24 and classified as a member of the expanding IL-10 cytokine gene family. Expression of mda-7/IL-24 inversely correlates with melanoma progression and administration of mda-7/IL-24 by means of a replication incompetent adenovirus, Ad.mda-7, results in growth suppression and apoptosis in melanoma cells as well as in a broad-spectrum of additional cancer cell types. In contrast, Ad.mda-7 does not elicit deleterious effects in normal cells, including those of epithelial, fibroblast, astrocyte, melanocyte or endothelial origin. Based on these distinctive properties and anti-tumor and anti-angiogenic activities in human tumor xenograft animal models, mda-7/IL-24 has now entered the clinical arena. A Phase I/II clinical trial in patients with advanced carcinomas involving intratumoral administration of mda-7/IL-24 [using a replication incompetent adenovirus; ING241 (Ad.mda-7)] has documented that this gene is safe and well tolerated by patients and a single virus injection elicits apoptosis in a majority of the tumor. Current data suggests that mda-7/IL-24 may function as a dual-acting cytokine in which its normal physiological functions may be related to specific aspects of the immune system and over-expression culminates in cancer-specific apoptosis. This review will provide a prospectus of our current understanding of mda-7/IL-24.
AB - An obstacle to effective gene-based cancer therapies is the limited number of cancer-specific growth suppressing and apoptosis-inducing genes. Using a differentiation induction subtraction hybridization (DISH) approach with human melanoma cells, melanoma differentiation associated (mda) genes were isolated that display elevated expression as a function of irreversible growth arrest, cancer reversion and terminal differentiation. This screening paradigm resulted in the cloning of mda-7 in the context of terminal differentiation of human melanoma cells. Based on its structure, chromosomal location, sequence homology and cytokine-like properties, mda-7 has now been renamed IL-24 and classified as a member of the expanding IL-10 cytokine gene family. Expression of mda-7/IL-24 inversely correlates with melanoma progression and administration of mda-7/IL-24 by means of a replication incompetent adenovirus, Ad.mda-7, results in growth suppression and apoptosis in melanoma cells as well as in a broad-spectrum of additional cancer cell types. In contrast, Ad.mda-7 does not elicit deleterious effects in normal cells, including those of epithelial, fibroblast, astrocyte, melanocyte or endothelial origin. Based on these distinctive properties and anti-tumor and anti-angiogenic activities in human tumor xenograft animal models, mda-7/IL-24 has now entered the clinical arena. A Phase I/II clinical trial in patients with advanced carcinomas involving intratumoral administration of mda-7/IL-24 [using a replication incompetent adenovirus; ING241 (Ad.mda-7)] has documented that this gene is safe and well tolerated by patients and a single virus injection elicits apoptosis in a majority of the tumor. Current data suggests that mda-7/IL-24 may function as a dual-acting cytokine in which its normal physiological functions may be related to specific aspects of the immune system and over-expression culminates in cancer-specific apoptosis. This review will provide a prospectus of our current understanding of mda-7/IL-24.
UR - http://www.scopus.com/inward/record.url?scp=0345801105&partnerID=8YFLogxK
U2 - 10.4161/cbt.458
DO - 10.4161/cbt.458
M3 - Review article
C2 - 14508078
AN - SCOPUS:0345801105
SN - 1538-4047
VL - 2
SP - S23-37
JO - Cancer biology & therapy
JF - Cancer biology & therapy
IS - 4 Suppl 1
ER -